

## **LIST OF TABLES**

### **2.1 List of Tables**

Table 1: MDR Gram-Negative Infections – Drivers and Barriers, 2013

Table 2: 6MM Unmet Needs – Current Level of Attainment

Table 3: Push Incentives Overview

Table 4: Pull Incentives Overview

Table 5: Hybrid Incentives Overview

Table 6: Role of Big Pharma in Antibiotic R&D

Table 7: Role of Academic and SME Entities in Antibiotic R&D

Table 8: Role of Government Agencies in Antibiotic R&D

### **2.2 List of Figures**

Figure 1: Opportunity Analysis – Clinical and Commercial Impact (Executive Summary)

Figure 2: Role of Push and Pull Incentives in Fostering Antibiotic R&D

Figure 3: Separate Review of Antibiotics Against MDR Gram-Negative Bacteria Enables Pragmatic Evaluation

Figure 4: The Traditional and Partnership Approaches to Antibiotic R&D

Figure 5: Opportunity Analysis – Clinical and Commercial Impact

Figure 6: Outline of Push and Pull Incentives for Antibiotic Development

Figure 7: Regulatory Trends in Antibiotic Drug Development

Figure 8: Traditional and Partnership Business Models in Antibiotic R&D